BackPathfinder Cell Therapy Overview

Pathfinder Cell Therapy Long Term Debt

Pathfinder Cell Therapy's long-term debt is $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer average

Loading

Pathfinder Cell Therapy Long Term Debt History

Loading

Pathfinder Cell Therapy vs. peers: Long Term Debt Comparison

Loading

Pathfinder Cell Therapy Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Pathfinder Cell Therapy (PFND) FAQ

Pathfinder Cell Therapy (PFND) currently reports a long-term debt of $0 as of September 2015. In the prior-year period, the figure was $0. Use the charts on this page to explore Pathfinder Cell Therapy's long-term debt history and peer comparisons.

Pathfinder Cell Therapy's long-term debt changed from $0 to $0 (period ending September 2015). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Pathfinder Cell Therapy reported $0 in long-term debt as of September 2015. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Pathfinder Cell Therapy, and consider following PFND for alerts when major investors trade the stock.

Pathfinder Cell Therapy is classified in the Healthcare sector. On long-term debt, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PFND with unrelated industries.